Leading a Generational Shift in the Osteoporosis Treatment Market

Daewoong Pharmaceutical announced on April 2 that 'Stoboclo' (active ingredient: denosumab), an osteoporosis treatment it is jointly marketing with Celltrion Pharm, has surpassed cumulative sales of 11.8 billion won in its first year on the market.


Stoboclo is the first domestic biosimilar of 'Prolia' (active ingredient: denosumab), a global blockbuster osteoporosis treatment. It was first launched in March of last year and marked its one-year anniversary on March 19.

Stovoclo product jointly marketed by Daewoong Pharmaceutical and Celltrion Pharm. Daewoong Pharmaceutical

Stovoclo product jointly marketed by Daewoong Pharmaceutical and Celltrion Pharm. Daewoong Pharmaceutical

View original image

According to market research firm IQVIA, Stoboclo achieved cumulative sales of approximately 11.8 billion won through the fourth quarter of last year, entering the blockbuster segment with annual domestic sales exceeding 10 billion won. The osteoporosis treatment market in Korea is estimated to be worth about 360 billion won as of 2025. Of this, the denosumab segment accounts for about 160 billion won, representing 45% of the total market. Stoboclo rapidly grew to secure a market share of approximately 14% in the denosumab segment as of the fourth quarter last year, and achieved a stable foothold in the market with about 7% annual cumulative market share.


Given its launch date, this achievement was reached in just about 10 months. This represents the fastest growth among denosumab-based biosimilars introduced to the Korean market, and Stoboclo has established itself as a 'First Mover' by earning strong trust from healthcare professionals and patients from the outset.


Building on this accomplishment, Daewoong Pharmaceutical plans to gradually expand prescriptions in major general and university hospitals nationwide, aiming to develop Stoboclo into a 'mega-blockbuster' with annual sales exceeding 100 billion won. Currently, Stoboclo is being prescribed at more than 50 major general and university hospitals across the country, rapidly expanding its reach. Through its robust partnership with Celltrion Pharm, the company intends to accelerate generational change in Korea’s osteoporosis treatment market.


The rapid growth of Stoboclo is attributed to its significant reduction of patients’ financial burden, the clinical efficacy recognized by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and the strong sales and marketing capabilities of Daewoong Pharmaceutical.


In fact, compared to the original drug, which cost over 200,000 won when first covered by insurance, Stoboclo was launched at a reasonable price of about 100,000 won—roughly half the cost. With insurance coverage, the actual out-of-pocket expense for patients is about 180 won per day, or approximately 5,400 won per month. This offers patients access to ongoing treatment and fracture risk prevention for the price of a cup of coffee each month.


The main ingredient in Stoboclo, denosumab, has the advantage of maintaining efficacy for six months with a single injection. Compared to other osteoporosis treatments that require daily dosing or injections every week or every three months, patient adherence is higher. As a result, it reduces both the treatment burden and the number of hospital visits for patients, and even lessens the administration burden for healthcare providers.


Notably, while Stoboclo is more reasonably priced than the original product, it also offers improved convenience and safety for users. The syringe is designed so that the needle automatically retracts into the body after injection, minimizing the risk of needlestick injuries. In addition, a 'latex-free' material was applied to the cap covering the needle, so even patients with latex allergies can use it with confidence.


Stability in storage and distribution has also been greatly enhanced. Stoboclo is designed to be stored at room temperature (up to 30°C) for up to 63 days, as confirmed by formulation stability tests. This is about four times longer than previous products, reducing the risk of drug degradation due to mishandling during storage or distribution.



Park Hyungcheol, Head of ETC Marketing Division at Daewoong Pharmaceutical, stated, "The achievement of 11.8 billion won in sales during Stoboclo’s first year is the result of the product's excellent quality combined with a differentiated marketing strategy," and added, "We will continue to do our utmost to ensure that more osteoporosis patients can benefit from treatment, based on affordable pricing and outstanding product capabilities."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing